Bristol-Myers Squibb

Bristol-Myers SquibbBristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

www.bms.com.

Bristol-Myers Squibb RSS Channel

Filters
List of articles in category Bristol-Myers Squibb
Title Published Date
Bristol-Myers Squibb - Pfizer Alliance ACROPOLIS™ real-world data program grows to sample size of nearly one million lives worldwide 20 August 2018
Bristol-Myers Squibb announces worldwide collaboration with Janssen to develop and commercialize next-generation cardiovascular therapy 16 April 2018
Bristol-Myers Squibb and Harvard announce new fibrosis research collaboration 12 April 2018
Bristol-Myers Squibb's Opdivo® (nivolumab) now the first and only FDA-approved PD-1 inhibitor to offer every four-week dosing 07 March 2018
Bristol-Myers Squibb announces expansion of the International Immuno-Oncology Network (II-ON) with addition of Yale Cancer Center 01 March 2018
Bristol-Myers Squibb and Nektar Therapeutics announce global development & commercialization collaboration for Nektar's CD122-biased agonist, NKTR-214 15 February 2018
Bristol-Myers Squibb and Pfizer Alliance urge people to 'Tune in to AFib, Take Note of Stroke Risk' 05 December 2017
Bristol-Myers Squibb awards "Golden Tickets" for LabCentral to Neutrolis, Remora Therapeutics 28 November 2017
BMS-Pfizer Alliance to unveil real-world data analyses - cost, safety and comparative effectiveness findings associated with oral anticoagulants in non-valvular atrial fibrillation 10 November 2017
FDA accepts Bristol-Myers Squibb's application for Opdivo (nivolumab) in patients with resected high-risk advanced melanoma and grants priority review 17 October 2017
Caregivers wish liver cancer received greater public awareness in the U.S., new survey reveals 04 October 2017
AbbVie and Bristol-Myers Squibb announce clinical research collaboration to evaluate a therapeutic regimen in advanced solid tumors 22 September 2017
Bristol-Myers Squibb and Halozyme enter global collaboration and license agreement for ENHANZE technology 14 September 2017
Bristol-Myers Squibb completes previously announced acquisition of IFM Therapeutics 07 September 2017
Bristol-Myers Squibb employees ride across the U.S. to raise money to support cancer research by Stand Up To Cancer 06 September 2017
Bristol-Myers Squibb announces topline results from CheckMate -214 15 August 2017
Bristol-Myers Squibb to acquire IFM Therapeutics to strengthen oncology pipeline focus on innate immunity 03 August 2017
Bristol-Myers Squibb and Clovis Oncology announce a broad clinical collaboration 31 July 2017
U.S. Food and Drug Administration expands approval of Yervoy® (ipilimumab) to include pediatric patients 12 years and older with unresectable or metastatic melanoma 24 July 2017
Bristol-Myers Squibb to sell manufacturing facility in Swords, Ireland to SK Biotek Co., Ltd. 16 June 2017

Business & Industry

Research & Development

Conferences & Events

Regulatory Affairs